Levels of thrombin activatable fibrinolysis inhibitor in gestational diabetes mellitus

References

• Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin – activatable fibrinolysis inhibitor. J Biol Chem 1995;270:14477–84
   PubMed Web of Science ®Google Scholar
• Karakurt F, Gumus II, Bavbek N, et al. “Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome”. Gynecol Endocrinol 2008;24:491–7
   PubMed Web of Science ®Google Scholar
• Van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000;95:2855–99
   PubMed Web of Science ®Google Scholar
• Silveira A, Schatteman K, Goossens F, et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000;84:364–8
   PubMed Web of Science ®Google Scholar
• Bremme K, Ostlund E, Almqvist I, et al. Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and the puerperium. Obstet Gynecol 1992;80:132–7
   PubMed Web of Science ®Google Scholar
• Comeglio P, Fedi S, Liotta AA, et al. Blood clotting activation during normal pregnancy. Thromb Res 1996;84:199–202
   PubMed Web of Science ®Google Scholar
• Jonasson A, Larsson B, Lecander I, Astedt B. Placental and decidual u-PA, t-PA, PAI-1 and PAI-2 concentrations, as affected by cervical dilatation with laminaria tents or Hegar dilators. Thromb Res 1989;53:91–7
   PubMed Web of Science ®Google Scholar
• Cerneca F, Ricci G, Simeone R, et al. Coagulation and fibrinolysis changes in normal pregnancy: increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis. Eur J Obstet Gynecol Reprod Biol 1997;73:31–6
   PubMed Web of Science ®Google Scholar
• Watanabe T, Minakami H, Sakata Y, et al. Changes in activity of plasma thrombin activatable fibrinolysis inhibitor in pregnancy. Gynecol Obstet Invest 2004;58:19–21
   PubMedGoogle Scholar
• Chabloz P, Reber G, Boehlen F, et al. TAFI antigen and D-dimer levels during normal pregnancy and at delivery. Br J Haematol 2001;115:150–2
   PubMed Web of Science ®Google Scholar
• Chetaille P, Alessi MC, Kouassi D, et al. Plasma TAFI antigen variations in healthy subjects. Thromb Haemost 2000;83:902–5
   PubMed Web of Science ®Google Scholar
• Kim C, Newton KM, Knopp RH. Gestational diabetes and the ncidence of type-2 diabetes: a systematic review. Diabetes Care 2002;25:1862–8
   PubMed Web of Science ®Google Scholar
• Kousta E, Lawrence NJ, Godstand IF, et al. Insulin resistance and beta-cell dysfunction in normoglycaemic European women with a history of gestational diabetes. Clin Endocrinol 2003;59:289–97
   PubMedGoogle Scholar
• Anastasiou E, Öekakis JP, Alevizaki M, et al. Impaired endothelium-dependent vasodilatation in women with previous gestational diabetes. Diabetes Care 1998;21:2111–15
   PubMed Web of Science ®Google Scholar
• Meigs JB, Mittleman M, Nathan D. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: The Framingham Offspring Study. JAMA 2000;283:221–8
   PubMed Web of Science ®Google Scholar
• Hulthe J, Bokemark L, Wikstrand J, Fagerberg B. The metabolic syndrome, LDL particle size and atherosclerosis: the atherosclerosis and insulin resistance (AIR) Study. Arterioscler Thromb Vasc Biol 2000;20:2140–7
   PubMed Web of Science ®Google Scholar
• Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287:2570–81
   PubMed Web of Science ®Google Scholar
• Standards of medical care in diabetes – 2007. Diabetes Care American Diabetes Association 2007;30:S4–41
   Google Scholar
• Binette TM, Taylor FB Jr, Peer G, Bajzar L. Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon. Blood 2007;110:3168–75
   PubMedGoogle Scholar
• Hori Y, Gabazza EC, Yano Y, et al. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:660–5
   PubMed Web of Science ®Google Scholar
• Antovic JP, Yngen M, Ostenson CG, et al. Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications. Blood Coagul Fibrinol 2003;14:551–6
   PubMed Web of Science ®Google Scholar
• Harmanci A, Kandemir N, Dagdelen S, et al. Thrombin-activatable fibrinolysis inhibitor activity and global fibrinolytic capacity in type 1 diabetes: evidence for normal fibrinolytic state. J Diabetes Complicat 2006;20:40–4
   PubMed Web of Science ®Google Scholar
• Kvasnicka J, Bendl J, Zivny J, et al. Changes in hemostasis and fibrinolysis in gestational diabetes. Cas Lek Cesk 1996;135:106–10
   PubMedGoogle Scholar
• Bendl J, Kvasnicka J, Umlaufova A, et al. Hemostasis and levels of cytoadhesion molecules in gestational diabetes. Ceska Gynekol 1999;64:83–6
   PubMedGoogle Scholar
• Antovic JP, Rafik Hamad R, Antovic A, et al. Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation. Thromb Haemost 2002;88:644–7
   PubMedGoogle Scholar
• Alacacioğlu I, Ozcan MA, Alacacioğlu A, et al. Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women. Thromb Res 2004;114:155–9
   PubMedGoogle Scholar
• Dusse LM, Cooper AJ, Lwaleed BA. Thrombin activatable fibrinolysis inhibitor (TAFI): a role in pre-eclampsia? Clin Chim Acta 2007;378:1–6
   PubMedGoogle Scholar
• De Maat MP, Jansen MW, Hille ET, et al. Preeclampsia and its interaction with common variants in thrombophilia genes. J Thromb Haemost 2004;2:1588–93
   PubMed Web of Science ®Google Scholar
• Svensson AM, Waters BL, Laszik ZG. The protein C system in placental massive perivillous fibrin deposition. Blood Coagul Fibrinolysis 2004;15:491–5
   PubMedGoogle Scholar
• Van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin-activatable fibrinolysis inhibitor and risk for deep vein thrombosis. Blood 2000;95:2855–9
   PubMed Web of Science ®Google Scholar
• Eichinger S, Schonauer V, Weltermann A, et al. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 2004;103:3773–6
   PubMedGoogle Scholar
• Akinci B, Demir T, Saygili S, et al. Gestational diabetes has no additional effect on plasma thrombin-activatable fibrinolysis inhibitor antigen levels beyond pregnancy. Diabetes Res Clin Pract 2008;81:93–6
   PubMedGoogle Scholar
• Folkeringa N, Korteweg FJ, Veeger NJ, et al. Thrombin activatable fibrinolysis inhibitor (TAFI) is not associated with fetal loss, a retrospective study. Thromb Res 2009;123:511–4
   PubMedGoogle Scholar
• Guven GS, Kilicaslan A, Oz SG, et al. Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity. Clin Appl Thromb Hemost 2006;12:364–8
   PubMedGoogle Scholar